logo

SAVIENT PH(NSDQ:SVNT)
Savient Pharmaceuticals, Inc is a specialty pharmaceutical company with expertise in developing, manufacturing, and marketing human health care products for niche and wider markets. Products marketed by Savient''s sales force in the United States are Oxandrin (oxandrolone, USP) and Delatestryl (testosterone enanthate). Their subsidiary, Rosemont Pharmaceuticals Limited, develops, manufactures, and markets through its own sales force oral liquid formulations of prescription products for the UK pharmaceutical market.
# Employees: 73
Address: One Tower Center 14th Floor,East Brunswick,NJ,USA
Phone: 732 418-9300
Fax: 732 418-0570
Website: www.savientpharma.com
Email: information@savient.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Christopher Clement (Presi.; C.E.O.; Dir.)
Brian J. Hayden (Sr. V.P.; C.F.O.; Treas.)
Zebulun D. Horowitz M.D. (Sr. V.P.; Chief Medical Off.)
Paul Hamelin (Sr. V.P.; Commercial Opera.)
Robert K. Lamm Esq. (Sr. V.P. Quality & Regulatory Aff.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/24/2010
Mean EPS (Next Qtr): ($0.28)
Mean EPS (Year): ($1.84)
Mean Estimate(Long Term): ($0.01)
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 8
Shares Performance
Period SVNT Compare to S&P
YTD 138.51 % 97.40 %
4 Weeks -0.50 % -1.58 %
12 Weeks 0.66 % -5.10 %
Shares Information
Analyst Coverage: Y
Avg Volume: 1229338
Shares Outstanding: 61M
Market Cap: $0.85B
52 Week High: $16.24
52 Week Low: $3.06
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 SVNT split by factor of 0.020
Earnings Performance
EPS Growth in Last Quarter: -31.25 %
EPS Growth in Last Year: -31.25 %
Sales Growth in Last Quarter: -51.76 %
Sales Growth in Last Quarter: -39.48 %
Financials
Qtr Book Value: $1,105.19
Cash Flow/Share: ($0.01)
Change in Payout Ratio: -0.010
Price/Sales: 266.440
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia